1. Approaches to high-risk resected stage II and III melanoma;Yushak;Am Soc Clin Oncol Educat Book.,2019
2. Metastatic melanoma and immunotherapy;Herzberg;Clin. Immunol.,2016
3. Adverse events in cancer immunotherapy;Abdel-Wahab;Adv Exp Med Biol.,2017
4. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition;Buchbinder;Am J. Clin. Oncol.,2016
5. Common Terminology Criteria for Adverse Events (CTCAE). 2017:147. [consultado 20 Dic 2019]. Disponible en: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.